Jazz Pharmaceuticals receives FDA approval for rare veno-occlusive disease treatment
March 31, 2016Research and Development, Sales and Marketing FDA, jazz pharmaceuticals
Jazz Pharmaceuticals (NASDAQ: JAZZ) has announced that the US Food and Drug Administration (FDA) has granted marketing approval for Defitelio …
Actinium gets Orphan Drug Designation for myeloid leukaemia drug
March 31, 2016Research and Development Actinium Pharmaceuticals
New York-based biopharma Actinium Pharmaceuticals (NYSE MKT: ATNM) has received orphan drug designation from the US FDA for Iomab-B, a …
Janssen-Cilag’s HIV treatment gets NHS backing
March 31, 2016Manufacturing and Production, Research and Development, Sales and Marketing HIV, Janssen, NHS, drug trial
Janssen-Cilag Ltd (Janssen) has said NHS England (NHSE) will fund its combination treatment for HIV. The company said following the …
Roche to initiate testing for Zika virus under FDA investigational new drug application approval
March 31, 2016Manufacturing and Production, Research and Development Roche, Zika
Roche (SWX: RO) has announced that the US Food and Drug Administration (FDA) has provided approval to initiate the collection …
Bio Products Laboratory gets European approval for bleeding disorder treatment
March 30, 2016Research and Development, Sales and Marketing Bio Products Laboratory, Coagadex, human coagulation factor X
UK-based Bio Products Laboratory has received marketing authorisation from the European Medicines Agency for Coagadex – a drug which treats …
Biogen appoints Michel Vounatsos executive vice president, chief commercial officer
March 30, 2016Research and Development, Sales and Marketing
Biogen has appointed Michel Vounatsos as executive vice president and chief commercial officer, from April 18, 2016. Vounatsos will oversee …
Life sciences strength will drive UK pharma sector growth
March 30, 2016Sales and Marketing
The UK pharmaceutical market is set to grow from $28.8 billion in 2015 to approximately $43 billion by 2020, at …
US lawmakers demand price cut for Astellas, Medivation’s prostate cancer drug Xtandi
March 30, 2016Business Services, Manufacturing and Production, Research and Development, Sales and Marketing Astellas, Japan, Medivation, US FDA, Xtandi, drug price
US lawmakers have asked the National Institutes of Health and the Department of Health and Human Services to ‘use its …
Shire wins v Allergan in Lialda patent case
March 30, 2016Research and Development, Sales and Marketing Allergan, Shire, lialda
A US district court has ruled that Shire’s patent for ulcerative colitis drug Lialda is valid through 2020, leaving Allergan …
Keryx Biopharmaceuticals announces positive Phase III study results for anaemia treatment
March 30, 2016Research and Development CKD, anaemia, chronic kidney disease, clinical trial, dialysis, keryx, keryx biopharmaceuticals, kidney, phase 3, phase III
Keryx Biopharmaceuticals (NASDAQ: KERX) has announced positive top-line results for its Phase III study of ferric citrate for the treatment …
Sun Pharma forays into Japan with $293 million product buy from Novartis
March 30, 2016Manufacturing and Production, Research and Development, Sales and Marketing Japan, M&A, MA, Novartis, Sun Pharma, generics
Shares of Sun Pharma (BOM: 524715), the largest Indian drug maker rose over 2% Wednesday as the company announced the …
Eisai announces agreement to set up new gastrointestinal speciality company
March 30, 2016Manufacturing and Production, Research and Development, Sales and Marketing Ajinomoto, Eisai, absorption, acquisition, ea pharma, gastrointestinal, merger, speciality
Eisai (TYO: 4523) and Ajinomoto Co. (TYO: 2802) have announced an agreement to establish a new gastrointestinal speciality pharmaceutical company, …
FDA says positives outweigh risks on Acadia’s Parkinson’s psychosis drug
March 30, 2016Research and Development, Sales and Marketing FDA, Parkinson's, Parkinsons, acadia, nuplazid, pimavanserin, psychosis
Acadia Pharmaceuticals (NASDAQ: ACAD) has announced a positive result from the US Food and Drug Administration (FDA) concerning Nuplazid (pimavanserin) …
Biosimilars could save healthcare systems $100bn by 2020
March 30, 2016Research and Development, Sales and Marketing biosimilars
The growth of the market for biosimilar drugs has the potential to save EU and US healthcare systems up to …
Lupin drops on FDA observations; company reassures of no disruption at facility
March 29, 2016Business Services, Manufacturing and Production, Sales and Marketing Lupin, US FDA, regulation
Shares of India’s Lupin dropped over 14% Tuesday following news the US Food and Drug Administration (FDA) has made observations …
GSK’s Nucala gets regulatory approval in Japan to treat bronchial asthma
March 29, 2016Manufacturing and Production, Research and Development GlaxoSmithKline, Japan, Nucala, US FDA, bronchial asthma
GlaxoSmithKline (LSE: GSK) on Tuesday said the Japanese regulators have approved its drug to treat bronchial asthma. The Japanese Ministry …
Valeant’s outgoing CEO subpoenaed by US congressional committee
March 29, 2016Medical Communications, Research and Development Drug pricing, Michael Pearson, US, Valeant, committee, pearson, pharma, price hikes, senate aging committee, subpoena, subpoenaed
The US Senate Aging Committee has announced the issuing of a subpoena to the outgoing CEO of Valeant Pharmaceuticals, Michael …
TREND: Rare disease, cancer drugs will drive pharma M&A’s, growth
March 29, 2016Manufacturing and Production, Research and Development, Sales and Marketing M&A, MA, Orphan Drugs, cancer drugs
Moody’s Investor Service lowered its growth outlook for the global pharma sector but maintained the mergers and acquisitions in the …
Novo Nordisk breaks ground on new $2 billion production facility in North Carolina
March 29, 2016Manufacturing and Production, Research and Development $2 billion, Clayton, Novo, Novo Nordisk, building, diabetes, nordisk, north carolina, production facility
Novo Nordisk has begun work on a new $2 billion production facility in Clayton, North Carolina, which will produce active …
US FDA issues observations for Natco Pharma’s Indian plants
March 29, 2016Manufacturing and Production, Research and Development, Sales and Marketing
Shares in India-based Natco Pharma (BOM: 524816) dropped on the Bombay Stock Exchange following news the US Food and Drug …
Latest content
One in three UK women with migraine say symptoms taken less seriously
Report highlights scope to expand day surgery
Sygnature formalises drug discovery collaboration with X-Chem
Codis appoints Steven Facer as chief commercial officer
Danish medical cannabis use rises as regulator reports no new safety signals
